Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Anthera Pharmaceuticals
NCT07371468 · Systemic Lupus Erythematosus
NCT07617740 · REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), and more
NCT07409181 · Systemic Lupus Erythematosus
NCT07043153 · Systemic Lupus Erythematosus Disease
Investigator Site 103
Birmingham, Alabama
Investigator Site 113
Long Beach, California
Investigator Site 110
Upland, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions